Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $4.33M fell 35.1% year over year, behind the -33.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 36.6% from the prior quarter. Over 3 fiscal years it compounded at -6.0% a year.

Context

  • Stock-based compensation amounted to 37.8% of revenue in FY2025, up 10.3 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -33.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.33M-36.6% QoQ
Last fiscal yearDec 2025
$25.41M-33.1% YoY
LTMMar 2026
$23.07M-33.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.1%——
1 year-33.1%——
3-year CAGR-6.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
25.41M USD
Year-over-year change
-33.1%
4-year CAGR
-3.2%

Stock-Based Compensation vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.2% is the 7th highest of 9, against a peer median of -20.5%.
  • Stock-based compensation amounts to 50.9% of revenue for ARCT, versus a peer median of 12.3%.
ARCT Competitors
Stock-Based Compensation for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M USD-20.0%+6.1%—
VIRVir Biotechnology, Inc.LTM Mar 2026$35.01M USD+17.1%-21.7%53.5%
NVAXNovavax, Inc.LTM Mar 2026$33.45M USD-28.6%-34.9%5.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M USD-33.2%-6.0%50.9%
ABUSArbutus Biopharma CorporationLTM Mar 2026$18.43M USD+74.9%-1.1%9.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M USD-62.1%-23.7%—
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
BNTCBenitec Biopharma Inc.LTM Mar 2026$12.56M USD+183.6%+171.6%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$3.06M USD-44.1%-45.0%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
VALNValneva SELTM Mar 2026€0 EUR——0.0%
Peer median (excluding ARCT) —-20.5%-17.8%12.3%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.